Trial · NCT00926328
Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis
NCT00926328, Phase 3, Completed, Colgate Palmolive; results first posted 2009-06-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis. Trials, record NCT00926328. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00926328
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis
- NCT number
- NCT00926328
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 120 participants, actual
- Lead sponsor
- Colgate Palmolive
- Conditions
- Gingivitis
- Interventions
- Triclosan, fluoride, Fluoride
- First posted
- 2009-06-23
- Last updated
- 2013-08-15
- Results first posted
- 2009-06-23
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Gingivitis Index | 6 months | Units on a scale 0 to 3 (0 = no inflammation , 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) |
| Primary | Plaque Index | 6 Months | Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Gingivitis Index | 6 months | Units on a scale | MEAN | |
| PRIMARY | Plaque Index | 6 Months | Per protocol | Units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Gingivitis Index | Experimental Treatment | 1.00 | Standard Deviation 0.17 | Units on a scale | |
| Gingivitis Index | Placebo Control | 1.27 | Standard Deviation 0.28 | Units on a scale | |
| Plaque Index | Experimental Treatment | 2.22 | Standard Deviation 0.49 | Units on a scale | |
| Plaque Index | Placebo Control | 2.88 | Standard Deviation 0.52 | Units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Experimental Treatment | 60 | |
| Overall Study | STARTED | Placebo Control | 60 | |
| Overall Study | COMPLETED | Experimental Treatment | 48 | |
| Overall Study | COMPLETED | Placebo Control | 46 | |
| Overall Study | NOT COMPLETED | Experimental Treatment | 12 | |
| Overall Study | NOT COMPLETED | Placebo Control | 14 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental Treatment | ||
| Total, all-cause mortality | Placebo Control | ||
| Total, other adverse events | Experimental Treatment | 0 | 60 |
| Total, other adverse events | Placebo Control | 0 | 60 |
| Total, serious adverse events | Experimental Treatment | 0 | 60 |
| Total, serious adverse events | Placebo Control | 0 | 60 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Experimental Treatment vs Placebo Control: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00926328
GET https://conductscience.org/api/trials/v1/NCT00926328/registered